---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-034220"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2025-04-11T23:59:59+00:00"
generated_at: "2026-05-23T15:58:01.292724+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Cara Therapeutics issues investor deck for pending merger with Tvardi (STAT3 fibrosis program)

## Summary
- Merger with Tvardi Therapeutics (STAT3 inhibitor developer for fibrosis) announced Dec 17, 2024; closing conditions remain.
- Investor presentation shared with potential investors outlines Tvardi's clinical pipeline and post-combination strategy.
- No new financial terms disclosed; forward-looking statements caution on risks related to closing timing and regulatory submissions.
- Tvardi focuses on oral small-molecule STAT3 therapies for fibrosis-driven diseases with significant unmet need.

## SEC filing metadata
- accession: 0001104659-25-034220
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2025-04-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465925034220/0001104659-25-034220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465925034220/tm2512145d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-034220
- JSON: https://secwatch.observer/filing/0001104659-25-034220.json
- Plain text: https://secwatch.observer/filing/0001104659-25-034220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.